BNB Plus Corp. (BNBX)

NCM – Real vaqt narxi. Valyuta: USD

0.47

+0.01 (1.07%)

Yopilishda: May 12, 2026, 4:00 PM EDT

0.46

-0.01 (-2.83%)

Bozor oldidan: May 13, 2026, 7:32 AM EDT

23.04.2026

BNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Order

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company"), today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has successfully completed production of its largest order in LineaRx history. The $1.2 million order, originally announced in January 2026 with shipments completing in early May 2026, was produced at historically higher margins with zero batch failures, demonstrating the technical excellence and manufacturing reliability of th.

20.04.2026

BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNB Plus" or the "Company"), a Nasdaq-listed digital asset treasury company focused on Binance's BNB token, today announced that its Board of Directors has authorized a formal review of strategic alternatives to maximize shareholder value and also provided an update on its Nasdaq listing status. Strategic Review and Treasury Value The strategic alternatives under consideration include, but are not limited to, a merger, reverse merger, b.

18.03.2026

BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), announced today that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has been granted a European patent by the European Patent Office (EPO) related to European Patent Application No.: 21882234.4 (EP4232569A1) entitled "Compositions and Methods for RNA Synthesis." The European patent grant follows a U.S. patent grant in 2024 and covers the composition of LineaRx's chemically modified RNA polymerase (.

24.02.2026

BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company") today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has received two new orders for LineaDNA from well-established developers of genetic medicines. Production and shipment of both orders is expected to be completed prior to June 2026. "We're pleased to receive these new orders from leading genetic medicine companies,” said Clay Shorrock, President and CEO of BNBX. “We believe our con.

05.02.2026

BNB Plus Corp. (BNBX) Appoints James Haft as Independent Board Director

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced the appointment of James Haft as an Independent Director and member of the Board's Nominating Committee, effective as of February 2, 2026. Mr. Haft is a recognized pioneer in digital asset investments and decentralized finance, bringing more than 35 years of experience spanning blockchain infrastructure, emerging markets, and traditional finance. Mr. Haft has served as a managing director at Bear.

27.01.2026

BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th

NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced that Chief Investment Officer Patrick Horsman, CFA and Chairman of the Board Joshua Kruger will present live at the Digital Asset Virtual Investor Conference hosted by Virtual InvestorConferences.com, on January 27th, 2026 at 1:00PM EST. DATE: January 27th, 2026 TIME: 1:00PM EST Register here Mr.

27.01.2026

BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company"), today announced that Chief Investment Officer Patrick Horsman, CFA and Chairman of the Board Joshua Kruger will present live at the Digital Asset Virtual Investor Conference hosted by Virtual InvestorConferences.com, on January 27th, 2026 at 1:00PM EST. DATE: January 27th, 2026 TIME: 1:00PM EST Register here Mr. Horsman and Mr. Kruger will be available for 1x1 meetings on January 27-29. Participants may schedule.

Videolar

No Data

There is no data to display

Press-relizlar

23.04.2026

BNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Order

20.04.2026

BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value

18.03.2026

BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform

24.02.2026

BNB Plus Corp. (BNBX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

BNB Plus Corp. (BNBX)

BNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Order

BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value

BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform

BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers

BNB Plus Corp. (BNBX) Appoints James Haft as Independent Board Director

BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th

BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th

Videolar

No Data

Press-relizlar

BNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Order

BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value

BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform

BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers

BNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Order

BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value

BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform

BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers

BNB Plus Corp. (BNBX) Appoints James Haft as Independent Board Director

BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th

BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th

Videolar

No Data

Press-relizlar

BNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Order

BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value

BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform

BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers

Search stocks

BNB Plus Corp. (BNBX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

BNB Plus Corp. (BNBX)

BNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Order

BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value

BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform

BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers

BNB Plus Corp. (BNBX) Appoints James Haft as Independent Board Director

BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th

BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th

Videolar

No Data

Press-relizlar

BNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Order

BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value

BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform

BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers

BNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Order

BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value

BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform

BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers

BNB Plus Corp. (BNBX) Appoints James Haft as Independent Board Director

BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th

BNB Plus Corp. (BNBX) to Present at the Digital Asset Virtual Investor Conference January 27th

Videolar

No Data

Press-relizlar

BNB Plus Corp. Completes Historic $1.2 Million LineaDNA™ Order

BNB Plus Corp. Announces Review of Strategic Alternatives to Maximize Shareholder Value

BNB Plus Corp. Announces European Patent Grant for Fundamental Technology Underlying its Linea™ IVT Platform

BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA™ from Genetic Medicine Developers